Egalet Surrenders Some Early Gains After Challenging FDA For MorphaBond Exclusivity

Loading...
Loading...

Egalet Corp EGLT shares are trading higher by $0.31 (7 percent) at $5.15 in Wednesday's session.

Before the open, the company announced its challenge to the FDA for MorphBond exclusivity is still being considered. That news instigated a modestly higher open and after a brief pullback, the issue found support just above Tuesday's close ($4.84) at $4.89 and continued its move higher.

The continuation rally has taken the issue all the way to $5.60. That level comes in just above the pair of highs from January 24 ($5.56) and January 25 ($5.53).

Since reaching that elevated level, Egalet's stock has drifted lower into the lower $5.00 handle.

Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...